Adicet Bio Reports $31.2 Million Net Loss in Q2 2025, Focuses on Lead Candidate ADI-001

Adicet Bio, Inc. reported a net loss of $31.2 million for the second quarter of 2025, a slight increase from the $29.9 million loss recorded in the same period of 2024. For the first half of 2025, the company’s net loss totaled $59.4 million, compared to $57.9 million for the first half of 2024. The company’s total operating expenses for the second quarter were $32.4 million, a marginal decrease from $32.8 million in the prior year. Research and development expenses rose by 10% to $28.4 million, driven by increased costs associated with contract development and manufacturing organizations (CDMOs) and facility-related expenses. In contrast, general and administrative expenses decreased by 43% to $4.0 million, primarily due to reduced payroll and personnel costs.

Adicet's financial position showed a significant decline in cash and cash equivalents, which fell to $34.7 million as of June 30, 2025, down from $56.5 million at the end of 2024. The company also reported a decrease in total current assets from $180.1 million to $127.7 million over the same period. The accumulated deficit increased to $557.3 million, reflecting the ongoing investment in research and development without any product revenue, as none of its candidates have yet received regulatory approval.

Strategically, Adicet has made notable changes to its pipeline, focusing on its lead candidate, ADI-001, which is currently in Phase 1 clinical trials for autoimmune diseases. The company has also prioritized ADI-212, a next-generation candidate targeting prostate cancer, while discontinuing the development of ADI-270. This strategic shift is accompanied by a workforce reduction of approximately 30%, aimed at streamlining operations and reallocating resources to its prioritized projects. The company anticipates incurring approximately $2.3 million in restructuring charges related to this workforce reduction.

Looking ahead, Adicet plans to file new Investigational New Drug (IND) applications every 12 to 18 months and aims to report preliminary clinical data for ADI-001 in the second half of 2025. The company has expressed confidence that its current cash reserves will be sufficient to fund operations for at least the next twelve months, although it acknowledges the need for additional financing to support ongoing development efforts. The company remains subject to various risks, including reliance on third-party suppliers and the regulatory approval process, which could impact its future financial performance and operational capabilities.